Fig. 1 · Structure
Documents & Downloads
Sotiburafusp alfa
Angiogenesis Inhibitor
Sotiburafusp alfa is a bispecific fusion protein designed to target angiogenesis through its humanized VEGFR-1 extracellular domain fragment, which is linked to a modified humanized IgG1-kappa anti-human PD-L1 heavy chain variant. This unique construct effectively inhibits angiogenesis by blocking crucial signaling pathways. Sotiburafusp alfa has potential applications in cancer research, particularly in immunotherapy and the study of tumor microenvironments.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 2637466-37-4 |
| Applications | Angiogenesis Inhibitor |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.